Volpara to showcase comprehensive product offerings at NCoBC 2023

Volpara Health Technologies Ltd, a global leader in software for the early detection of cancer, is attending this year’s National Consortium of Breast Centers (NCoBC) conference in Las Vegas to showcase its software advancements that are powering progressive breast centers.

AI tools and education for federal breast density inform efforts 
The US Food and Drug Administration (FDA) recently announced a federal regulation requiring all women to be notified—with standard language—of their breast density in mammography results letters. NCoBC marks the industry’s first conference since the announced regulation and Volpara will demonstrate its market leading software to assist providers in better serving women with dense breasts:

Also Read: Maze Therapeutics Announces New Clinical Data Supporting MZE001 as a Potential Treatment for Pompe Disease

• Volpara Scorecard is the number one artificial intelligence software for automated, volumetric breast density assessment. Research has shown that radiologists who assess breast density visually assign density categories inconsistently. With the new federal language of dense vs. non-dense, distinguishing a patient’s breast density between a BI-RADS category b and c accurately and consistently will be essential. Volpara Scorecard’s objective TruDensity algorithm is proven to reduce reader variability.
  
  
• Volpara Thumbnail goes the extra mile to help patients understand their own breast density with image-enhanced results letters. The innovative letter section shows both images of a patient’s own breast tissue, as well as sample images indicating the difference in breast density categories and its impact on their care options. These simple-to-understand explanations and visuals aim to increase patient engagement and are paired with access to an educational website offering a deeper dive into these topics.

Volpara also offers Professional Services to help customers educate referrers and patients and to maximize the value of dense breast screening programs.

Assess patient risk beyond breast cancer
Volpara Risk Pathways provides a smooth workflow for healthcare providers assessing hereditary and lifetime breast cancer risk. Volpara interfaces with major genetics labs—including Ambry, Myriad, Natera, and Invitae—to improve the test request process and results delivery. The Risk Pathways lab connections offer the freedom to select a preferred lab or work with multiple labs as needs and/or patient insurance coverage requirements change.

SOURCE: PR Newswire